Compare Stocks → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKUSNASDAQ:FBRXNASDAQ:GERNNASDAQ:PRVBOTCMKTS:WIZP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUSAkouos$13.29$13.29$2.32▼$13.60$490.88M-0.55344,411 shs440 shsFBRXForte Biosciences$0.74+2.8%$0.70$0.38▼$1.15$26.94M0.4832,476 shs2,304 shsGERNGeron$3.52-1.7%$2.83$1.64▼$4.05$1.92B0.6211.08 million shs6.36 million shsPRVBProvention Bio$24.98+3.1%$24.58$3.18▼$25.00$2.37B2.472.28 million shs9.12 million shsWIZPMawson Infrastructure Group$1.34-11.3%$1.45$0.07▼$1.45$651.67M1.77141,517 shs376,005 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUSAkouos0.00%0.00%0.00%0.00%0.00%FBRXForte Biosciences-3.87%-4.05%0.00%+3.59%-32.38%GERNGeron+2.29%-2.72%+9.82%+65.74%+47.93%PRVBProvention Bio0.00%0.00%0.00%0.00%+3.10%WIZPMawson Infrastructure Group-3.82%+46.60%-4.43%-28.44%-50.00%This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industryMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKUSAkouosN/AN/AN/AN/AN/AN/AN/AN/AFBRXForte Biosciences3.2963 of 5 stars3.35.00.00.02.22.51.3GERNGeron3.2734 of 5 stars3.53.00.01.31.41.70.6PRVBProvention BioN/AN/AN/AN/AN/AN/AN/AN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKUSAkouosN/AN/AN/AN/AFBRXForte Biosciences2.50Moderate Buy$2.75287.32% UpsideGERNGeron3.00Buy$5.3348.98% UpsidePRVBProvention BioN/AN/AN/AN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/ACurrent Analyst RatingsLatest FBRX, GERN, PRVB, AKUS, and WIZP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/10/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.004/8/2024FBRXForte BiosciencesLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$2.753/15/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.003/15/2024GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.003/15/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.002/28/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKUSAkouosN/AN/AN/AN/A$4.90 per shareN/AFBRXForte BiosciencesN/AN/AN/AN/A$0.97 per shareN/AGERNGeron$240K8,157.48N/AN/A$0.46 per share7.78PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84WIZPMawson Infrastructure GroupN/AN/AN/AN/A$0.03 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKUSAkouos-$86.67M-$2.62N/AN/AN/AN/A-45.09%-36.86%N/AFBRXForte Biosciences-$31.48M-$1.04N/AN/AN/AN/A-94.27%-81.36%5/20/2024 (Estimated)GERNGeron-$184.13M-$0.33N/AN/AN/A-77,691.14%-63.33%-44.71%5/9/2024 (Estimated)PRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/AWIZPMawson Infrastructure Group-$3.45M-$0.33N/AN/AN/AN/AN/A-85.32%N/ALatest FBRX, GERN, PRVB, AKUS, and WIZP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023FBRXForte BiosciencesN/A-$0.04-$0.04-$0.04N/AN/A2/28/2024Q4 23GERNGeron-$0.10-$0.09+$0.01-$0.09$0.06 million$0.02 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKUSAkouosN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKUSAkouosN/A17.3017.30FBRXForte BiosciencesN/A10.4510.45GERNGeron0.143.163.16PRVBProvention Bio0.191.931.92WIZPMawson Infrastructure GroupN/A1.131.13OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKUSAkouosN/AFBRXForte Biosciences77.63%GERNGeron73.71%PRVBProvention Bio37.39%WIZPMawson Infrastructure GroupN/AInsider OwnershipCompanyInsider OwnershipAKUSAkouos4.80%FBRXForte Biosciences10.53%GERNGeron3.10%PRVBProvention Bio13.10%WIZPMawson Infrastructure GroupN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKUSAkouos10336.94 million35.16 millionNot OptionableFBRXForte Biosciences936.40 million32.56 millionOptionableGERNGeron141546.87 million529.92 millionOptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableWIZPMawson Infrastructure Group2486.32 millionN/ANot OptionableGERN, PRVB, FBRX, WIZP, and AKUS HeadlinesSourceHeadlineMawson Infrastructure Group adds new customer at Midland bitcoin facilitybizjournals.com - December 20 at 11:39 AMMawson announces agreement for half of Midland bitcoin facility capacitybizjournals.com - October 19 at 5:32 PMMawson Infrastructure reports BTC production of 69 in July, down 3% M/Mseekingalpha.com - August 24 at 6:28 PMH.C. Wainwright Sticks to Its Buy Rating for Mawson Infrastructure Group (MIGI)markets.businessinsider.com - August 24 at 7:44 AMMawson Infrastructure Group Inc. Invites Submission of Indication of Interest for its BTC Hosting and HPC Co-location Servicestechnews.tmcnet.com - July 25 at 10:20 AMMawson Infrastructure Group Inc. Announces Monthly Operational Update for June 2023businesswire.com - July 19 at 10:01 AMMawson Infrastructure Group Inc. Announces Monthly Operational Update for May 2023technews.tmcnet.com - June 14 at 10:10 AMMawson Infrastructure Group names new president, CEObizjournals.com - May 22 at 12:56 PMWith Significant Increases In Megawatt Capacity And Bitcoin Production, Mawson Infrastructure Group (NASDAQ: MIGI) May Attract More Bitcoin Mining Investorsmsn.com - April 11 at 10:13 AMEarnings Outlook For Mawson Infrastructuremsn.com - November 12 at 8:40 PMBitcoin Miner CleanSpark Buys Mawson Site as Consolidation Risesfinance.yahoo.com - September 11 at 12:26 AMMawson Infrastructure Group Inc. To Sell Sandersville, Georgia Bitcoin Mining Facility including 6468 ASIC Bitcoin Miners To CleanSpark, Inc. For Up To $42.5 Millionbenzinga.com - September 9 at 10:20 AMWhy Bitcoin- And Ethereum-Related Stock CleanSpark Is Rising Todaybenzinga.com - September 9 at 10:20 AMMawson Infrastructure Group Inc. Announces July 2022 Bitcoin Self-Mining, Hosting Co-location, Energy Demand Response and Operational Updatefinance.yahoo.com - August 25 at 10:24 AMMawson Infrastructure Group Inc. Schedules Second Quarter Results Webcast for 5:30 p.m. ET on August 22, 2022benzinga.com - August 18 at 9:55 AMBitcoin Miner Mawson Infrastructure Produced 185 Bitcoin In Record-Breaking Maybitcoinmagazine.com - June 16 at 3:23 PMMawson to Develop New Bitcoin Mining Site in Texasfinance.yahoo.com - May 17 at 2:50 AMMawson Infrastructure Group Inc. Announces New 120 Megawatt Bitcoin Mining Facility in Texas, USAtmcnet.com - May 16 at 9:34 AMTexas Pacific Land Corporation, Mawson Infrastructure Group Inc., and JAI Energy Announce New Bitcoin Mining Venture in West Texastmcnet.com - May 16 at 9:34 AMMawson Infrastructure Group discusses Q3 highlights including Quinbrook renewable energy partnershipproactiveinvestors.com - December 14 at 11:45 PMAudacious Secures $20M Funding & Closes $3.1M Non-Brokered Private Placement Tranchebenzinga.com - December 11 at 11:01 PMEssential Investment? This REIT Believes in Cannabis-Related Real Estatebenzinga.com - December 9 at 6:25 PMSouth Dakota's Supreme Strikes Down Recreational Cannabis Vote, Overturning People's Willbenzinga.com - November 28 at 6:55 PM10 Weed Strains For People Who Like Cheesebenzinga.com - November 8 at 12:11 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkouosNASDAQ:AKUSAkouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.Forte BiosciencesNASDAQ:FBRXForte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.GeronNASDAQ:GERNGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Provention BioNASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.Mawson Infrastructure GroupOTCMKTS:WIZPMawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company is headquartered in North Sydney, Australia. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.